The Catholic University of Korea at ENA 2026
Nov 18–20, 2026 Barcelona, Spain ~1.5k attendees Website
The Catholic University of Korea brings 2 presentations to ENA 2026 in Barcelona. Its posters centre on dosing BAL0891, a first-in-class TTK/PLK1 inhibitor, in clinical trials. It models population pharmacokinetics and neutropenia risk from the dose-escalation trial and uses Bayesian benefit-risk analysis to pick the recommended phase 2 dose with paclitaxel in metastatic urothelial carcinoma.
| Organization | ENA 2026 Attendance |
|---|---|
The Catholic University of Korea Seoul, South Korea | |
Private university in Seoul whose college of medicine runs the Catholic Medical Center hospital network. | Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm |
Instantly find 20 buyers from The Catholic University of Korea
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by EORTC, the NCI or the AACR. Submit a correction